Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction

Summary

This study aims to evaluate the effect of sacubitril/valsartan in patients with prosthetic heart valves with heart failure with reduced ejection fraction (HFrEF).

Eligibility

Inclusion Criteria:

* Age ≥ 18 years old.
* Both sexes.
* Patients with a history of prosthetic heart valves.
* Patients diagnosed with heart failure with reduced ejection fraction (HFrEF), defined as left ventricular ejection fraction (LVEF) ≤ 40% with New York Heart Association (NYHA) functional class II-IV.

Exclusion Criteria:

* Hemodynamic instability.
* Use of a circulatory auxiliary circulation device.
* Severe hepatic \[alanine aminotransferase (ALT) \>120 U/L\] and renal insufficiency \[estimated glomerular filtration rate (eGFR) \<30 mL/min\].
* Blood pressure \<100/60 mmHg.
* Serum potassium \>5.3 mmol/L.
* Severe pulmonary hypertension.
* Malignant arrhythmia.
* Malignant tumor.
* Known history of hereditary or primary angioedema.
* Serious adverse drug reactions or serious complications over the course of treatment.

Conditions5

Interventions2

Related trials

• Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy — University of Edinburgh
• Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM) — Silesian Centre for Heart Diseases
• The Effect of Sacubitril/valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients with Ischemic Heart Failure with Mid-range Ejection Fraction — John Paul II Hospital, Krakow
• Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease — China National Center for Cardiovascular Diseases
• Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial — Khawaja Danish Ali
• Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts — Heart Center Research, LLC
• Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study — The Cleveland Clinic
• Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan — Virginia Commonwealth University

Browse More Trials